{
  "id": 3104880,
  "title": "Mizuho raises Insmed stock price target to $195 on Japan approval",
  "url": "https://urgent.news/2026/08/24/mizuho-raises-insmed-stock-price-target-to-195-on-japan-approval",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T20:25:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/mizuho-raises-insmed-stock-price-target-to-195-on-japan-approval-93CH-4874154"
  },
  "original_language": "en",
  "account": "Mizuho has hiked its price target on Insmed shares (NASDAQ:INSM) to $195, up from $192, following Japan's regulatory approval of Brinsupri. Insmed recently announced that Brinsupri has been approved in Japan for non-cystic fibrosis bronchiectasis in adults and children aged 12 or older. Mizuho has upgraded its probability-of-success assumption for Brinsupri in Japan to 100%, up from 90%. This new target implies a 55% upside from the current market price of $123.98. The stock now trades at $123.98 with a market capitalization of $27.1 billion, and the analyst consensus remains a \"strong buy\" rating of 1.22. Insmed reported a positive revenue beat for Brinsupri in the second quarter of 2026 on August 6 and raised guidance for both Brinsupri and TPIP. Despite a 6% decline in Insmed shares since the August 6 earnings report, the XBI biotech index has gained 7%. Mizuho maintains confidence in the Brinsupri launch and believes the current share weakness is unwarranted given the company's solid fundamentals.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}